Group 1 - Company received an administrative penalty from Tianjin Market Supervision Administration for engaging in a monopoly agreement to fix the price of Dexamethasone Phosphate Sodium raw materials, violating the Anti-Monopoly Law of the People's Republic of China [1] - The penalty includes the confiscation of illegal income amounting to 17,899,200.00 yuan and a fine of 43,139,047.84 yuan after a 30% reduction, totaling 61,038,247.84 yuan [1] - The penalty represents 2.83% of the company's audited revenue and 72.53% of the net profit attributable to shareholders for the most recent fiscal year [2] Group 2 - The penalty will reduce the company's net profit attributable to shareholders for the fiscal year 2025 by 61,038,247.84 yuan [2] - The administrative penalty does not trigger any mandatory delisting scenarios as per the Shanghai Stock Exchange listing rules and is not expected to have a lasting impact on the company's operations [2]
联环药业(600513.SH)收到《行政处罚决定书》